ES2628935T3 - N4 quelantes conjugados - Google Patents

N4 quelantes conjugados Download PDF

Info

Publication number
ES2628935T3
ES2628935T3 ES05763654.0T ES05763654T ES2628935T3 ES 2628935 T3 ES2628935 T3 ES 2628935T3 ES 05763654 T ES05763654 T ES 05763654T ES 2628935 T3 ES2628935 T3 ES 2628935T3
Authority
ES
Spain
Prior art keywords
compound
mmol
wide
tert
nch2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05763654.0T
Other languages
English (en)
Spanish (es)
Inventor
Anthony E STOREY
Harry Wadsworth
Nigel A POWELL
Philip Duncanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Application granted granted Critical
Publication of ES2628935T3 publication Critical patent/ES2628935T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES05763654.0T 2004-07-19 2005-07-19 N4 quelantes conjugados Expired - Lifetime ES2628935T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0416062 2004-07-19
GBGB0416062.8A GB0416062D0 (en) 2004-07-19 2004-07-19 Improved N4 chelator conjugates
PCT/GB2005/002807 WO2006008496A2 (en) 2004-07-19 2005-07-19 Improved n4 chelator conjugates

Publications (1)

Publication Number Publication Date
ES2628935T3 true ES2628935T3 (es) 2017-08-04

Family

ID=32893775

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05763654.0T Expired - Lifetime ES2628935T3 (es) 2004-07-19 2005-07-19 N4 quelantes conjugados

Country Status (14)

Country Link
US (1) US7767796B2 (enExample)
EP (1) EP1768708B1 (enExample)
JP (1) JP5557425B2 (enExample)
KR (2) KR20070034064A (enExample)
CN (1) CN101128219B (enExample)
AU (1) AU2005263942B2 (enExample)
BR (1) BRPI0513456A (enExample)
CA (1) CA2573384C (enExample)
ES (1) ES2628935T3 (enExample)
GB (1) GB0416062D0 (enExample)
MX (1) MX2007000744A (enExample)
NO (1) NO20070348L (enExample)
RU (1) RU2360701C2 (enExample)
WO (1) WO2006008496A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101732736B (zh) * 2009-12-02 2012-04-04 北京师范大学 制备锝-99m标记的DTPA-LSA的药盒及制备方法和应用
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
GB201016206D0 (en) * 2010-09-27 2010-11-10 Ge Healthcare Ltd Apoptosis imaging agents
RU2465011C1 (ru) * 2011-04-27 2012-10-27 Общество с ограниченной ответственностью "ИНТЕРА-МЕД" Радиофармацевтический препарат для диагностики меланомы и ее метастазов
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
RU2655392C1 (ru) * 2017-03-02 2018-05-28 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский политехнический университет" Способ получения комплекса технеция-99м с октреотидом для диагностики нейроэндокринных опухолей
WO2019222454A1 (en) 2018-05-16 2019-11-21 Emory University Styrylbenzothiazole derivatives and uses in imaging

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175343A (en) * 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
EP0188256B1 (en) * 1985-01-14 1991-08-21 NeoRx Metal radionuclide labeled proteins for diagnosis and therapy
US5242679A (en) * 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5053493A (en) * 1987-04-02 1991-10-01 Centocor Cardiovascular Imaging Partners, L.P. Method for labeling antibodies with a metal ion
DE3850497T2 (de) * 1987-04-02 1995-02-23 Centocor Inc Methode zur markierung von antikörpern mit einem metallion.
US4952393A (en) * 1987-04-02 1990-08-28 The General Hospital Corporation Organ infarct imaging with technetium labelled glucarate
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en) * 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
NZ250653A (en) * 1993-01-12 1995-12-21 Sandoz Ltd Somatostatin derivatives and pharmaceutical or diagnostic imaging compositions
JPH11513374A (ja) * 1995-09-18 1999-11-16 マリンクロッド・メディカル・インコーポレイテッド （放射性）標識化ビオチン誘導体類
GR1003661B (el) * 2000-05-25 2001-09-05 Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος"... ΣΥΝΘΕΣΗ, ΒΙΟΛΟΓΙΚΗ ΚΑΙ ΠΡΟΚΛΙΝΙΚΗ ΑΞΙΟΛΟΓΗΣΗ ΑΝΑΛΟΓΩΝ ΤΗΣ (D-Phe6, Leu-NHEt13, des-Met14)-ΒΟΜΒΕΣΙΝΗΣ (6-14)ΤΡΟΠΟΠΟΙΗΜΕΝΩΝ ΜΕ ΠΑ ΡΑΓΩΓΑ ΤΟΥ 1,4,8,11-ΤΕΤΡΑΑΖΑΕΝΔΕΚΑΝΙΟΥ(1,4,8,11-TETRAAZAUNDECAN E)ΚΑΙ ΕΠΙΣΗΜΑΣΜΕΝΩΝ ΜΕ ΤΕΧΝΗΤΙΟ-99M- ΓΙΑ ΕΦΑΡΜΟΓΗ ΣΤΗΝ ΟΓΚΟΛΟΓ
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
JP4510444B2 (ja) 2001-07-10 2010-07-21 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
GB0130305D0 (en) * 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
US7785566B2 (en) * 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds
US7431914B2 (en) * 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
JP2007526300A (ja) * 2004-03-04 2007-09-13 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物

Also Published As

Publication number Publication date
CN101128219B (zh) 2012-06-20
AU2005263942A1 (en) 2006-01-26
BRPI0513456A (pt) 2008-05-06
NO20070348L (no) 2007-02-16
GB0416062D0 (en) 2004-08-18
MX2007000744A (es) 2007-06-25
EP1768708B1 (en) 2017-05-17
US20080131368A1 (en) 2008-06-05
RU2360701C2 (ru) 2009-07-10
EP1768708A2 (en) 2007-04-04
KR20130024963A (ko) 2013-03-08
CA2573384C (en) 2013-09-10
JP5557425B2 (ja) 2014-07-23
RU2007101515A (ru) 2008-08-27
CN101128219A (zh) 2008-02-20
WO2006008496A2 (en) 2006-01-26
US7767796B2 (en) 2010-08-03
WO2006008496A3 (en) 2006-07-27
AU2005263942B2 (en) 2009-02-26
JP2008510683A (ja) 2008-04-10
CA2573384A1 (en) 2006-01-26
KR20070034064A (ko) 2007-03-27

Similar Documents

Publication Publication Date Title
AU2018382479B2 (en) PSMA ligands for imaging and endoradiotherapy
JP6169520B2 (ja) タンパク質薬剤接合体のための分枝リンカー
ES2628935T3 (es) N4 quelantes conjugados
WO1999020626A1 (en) Folic acid derivatives
AU2020213892B2 (en) Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof
PT1904460E (pt) Ligandos aza multidentados capazes de complexar iões metálicos e sua utilização em diagnósticos e terapia
RU2697519C1 (ru) Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
EP3494999A1 (en) Psma ligands for imaging and endoradiotherapy
AU2020306219B2 (en) Cyclen based compounds, coordination compounds, peptides, pharmaceutical preparation, and use thereof
ES2338164T3 (es) Compuestos para la inhibicion de la apoptosis.
RU2841078C1 (ru) Лиганды, тропные к простатическому специфическому мембранному антигену и их применение для получения двойных конъюгатов с терапевтическими агентами на их основе для комбинированной терапии псма экспрессирующих опухолей
이원창 Development of PSMA-targeting ligands for theranostic applications in prostate cancer
RU2807076C2 (ru) Лиганды PSMA для визуализации и эндорадиотерапии
HK40031508B (en) Psma ligands for imaging and endoradiotherapy